NDA 022307 · Cosette
Effient
Prasugrel Hydrochloride · Oral
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Dec 22, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Jul 10, 2009
Approved uses
3
Original approval plus efficacy supplements
Registered trials
209
48 Phase 3, 21 recruiting
FAERS reports
10,151
7,609 serious, 862 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: BLEEDING RISK Effient can cause significant, sometimes fatal, bleeding [see Warnings and Precautions (5.1 , 5.2) and Adverse Reactions (6.1) ] . Do not use Effient in patients with active pathological bleeding or a history of transient ischemic attack (TIA) or stroke [see Contraindications (4.1 , 4.2) ] . In patients ≥75 years of age, Effient is generally not recommended, because of the increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a history of prior myocardial infarction [MI]) where its effect appears to be greater and its use may be considered [see Use in Specific Populations (8.5) ] . Do not start Effient in patients likely to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue Effient at least 7 days prior to any surgery [see Warnings and Precautions (5.2)...
What it is approved for
From the label in effect Sep 7, 2022.
Effient is a P2Y 12 platelet inhibitor indicated for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI) as follows: Patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI) ( 1.1 ). Patients with ST-elevation myocardial infarction (STEMI) when managed with either primary or delayed PCI ( 1.1 ). 1.1 Acute Coronary Syndrome Effient ® is indicated to reduce the rate of thrombotic CV events (including stent thrombosis) in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI) as follows: Patients with unstable angina (UA) or non-ST-elevation myocardial infarction (NSTEMI). Patients with ST-elevation myocardial infarction (STEMI) when managed with primary or delayed PCI. Effient has been shown to reduce the rate of a combined endpoint of cardiovascular death, nonfatal myocardial infarction (MI), or nonfatal stroke compared to clopidogrel. The difference between treatments was driven predominantly by MI, with no difference on strokes and little difference on CV death [see Clinical Studies (14) ] .
Mechanism: Prasugrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y 12 class of ADP receptors on platelets.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 12, 2016 Supplement 14 · Efficacy · priority review OrphanLabelLetter
- Oct 16, 2013 Supplement 8 · Efficacy LabelReviewOther
- Jul 10, 2009 Original approval · Type 1 - New Molecular Entity · priority review NovelReviewOther Important Information from FDASummary Review
2 products under this application
- EFFIENT · PRASUGREL HYDROCHLORIDE EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB
- EFFIENT · PRASUGREL HYDROCHLORIDE EQ 5MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Prasugrel" as an intervention, any sponsor and status, largest first.
- The Dual Antiplatelet Therapy Study (DAPT Study)Pivotal-lookingCompleted
Baim Institute for Clinical ResearchAcademic, hospital or other
NCT00977938 · 25,682 participants · Start Oct 2009 · Primary completion Jun 2014
Drug: Placebo & Aspirin; Clopidogrel & Aspirin, Prasugrel & Aspirin · For: Coronary Artery Disease
Sites: Fairhope, Alabama; Gilbert, Arizona; Phoenix, Arizona · 256 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary SyndromePivotal-lookingCompleted
Vastra Gotaland RegionGovernment (non-federal)
NCT05183178 · 17,095 participants · Start Feb 1, 2022 · Primary completion Aug 31, 2025
Drug: Prasugrel 10 mg p.o; Ticagrelor 90 mg · For: Acute Coronary Syndrome
Sites: Lund, Sweden
- A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary InterventionPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00097591 · 13,619 participants · Start Nov 2004 · Primary completion Jul 2007
Drug: Prasugrel; Clopidogrel · For: Coronary Arteriosclerosis; Acute Coronary Syndromes
Sites: Indianapolis, Indiana
- A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome SubjectsPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00699998 · 9,326 participants · Start Jun 2008 · Primary completion Apr 2012
Drug: Clopidogrel; Prasugrel and 1 more · For: Acute Coronary Syndrome
Sites: Birmingham, Alabama; Huntsville, Alabama; Glendale, Arizona · 688 sites in all
- Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 MonthsPivotal-lookingRecruiting
Instituto de Investigación Sanitaria de la Fundación Jiménez DíazAcademic, hospital or other
NCT07507500 · 8,100 participants (planned) · Start Sep 2, 2026 · Primary completion Jul 2029
Drug: Prasugrel; Ticagrelor · For: Myocardial Infarction (MI)
Sites: Dublin, Ireland; Riga, Latvia; Oslo, Norway · 5 sites in all
- ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 StudyPivotal-lookingStatus unknown
Kyoto University, Graduate School of MedicineAcademic, hospital or other
NCT04609111 · 6,002 participants · Start Jan 29, 2021 · Primary completion Dec 31, 2023
Drug: No aspirin; 1-month DAPT · For: Acute Coronary Syndrome
Sites: Kyoto, Japan
- A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial InfarctionPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01015287 · 4,033 participants · Start Dec 2009 · Primary completion Jan 2013
Drug: Placebo; Prasugrel · For: Acute Coronary Syndromes
Sites: Braunau am Inn, Austria; Graz, Austria; Linz, Austria · 153 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- myocardial infarction510
- gastrointestinal haemorrhage472
- chest pain460
- haemorrhage454
- dyspnoea436
- contusion425
- fatigue333
- off label use324
- nausea308
- dizziness302
- thrombosis in device284
- epistaxis254
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 56 |
| 2010 | 598 |
| 2011 | 786 |
| 2012 | 827 |
| 2013 | 502 |
| 2014 | 545 |
| 2015 | 2,703 |
| 2016 | 817 |
| 2017 | 667 |
| 2018 | 503 |
| 2019 | 414 |
| 2020 | 259 |
| 2021 | 216 |
| 2022 | 379 |
| 2023 | 321 |
| 2024 | 167 |
| 2025 | 209 |
| 2026 | 181 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Effient (Prasugrel HCl)
2024 spending
$903K
Beneficiaries
188
858 claims
Per beneficiary
$4,805
$18.03 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $154,137 |
| 2023 | $1,033,195 |
| 2024 | $903,432 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI.
Takahashi K, Kozuma K, Morino Y, et al. · N Engl J Med 2026 · Multicenter Study, Randomized Controlled Trial
- Efficacy and Safety of Prasugrel, Ticagrelor, or Clopidogrel After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.
Maqsood MH, Feit F, Kaul U, et al. · JAMA Cardiol 2026 · Systematic Review, Meta-Analysis
- Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Wiviott SD, Braunwald E, McCabe CH, et al. · N Engl J Med 2007 · Clinical Trial, Phase III, Comparative Study
- Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes.
Guimarães PO, Franken M, Tavares CAM, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Equivalence Trial
- Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis.
Carvalho PEP, Gewehr DM, Nascimento BR, et al. · JAMA Cardiol 2024 · Systematic Review, Network Meta-Analysis
- Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.
Schüpke S, Neumann FJ, Menichelli M, et al. · N Engl J Med 2019 · Clinical Trial, Phase IV, Comparative Study
Sponsor: Cosette
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.